All Stories

  1. Albaconazole Polymeric Nanocapsules for Treating Trypanosoma cruzi Infections
  2. IR780-Based Nanotheranostics and In Vivo Effects: A Review
  3. Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease
  4. Impact of non-ionic surfactants on release kinetics, toxicity and colloidal characteristics of benznidazole self-emulsifying delivery system evidenced by flow field-flow fractionation
  5. Effects of continuous millifluidic process on the physicochemical properties and freeze-drying of cloxacillin benzathine-loaded nanocapsules
  6. Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status
  7. Screening of synthetic 1,2,3-triazolic compounds inspired by SRPIN340 as anti-Trypanosoma cruzi agents
  8. Lychnopholide loaded in surface modified polylactide nanocapsules (LYC-PLA-PEG-NC) cure mice infected by Trypanosoma cruzi strain a prototype of resistance to benznidazole and nifurtimox: First insights of its mechanism of action
  9. Novel Diamides Inspired By Protein Kinase Inhibitors As Anti- Trypanosoma Cruzi Agents: In Vitro and In Vivo Evaluations
  10. Polymeric Delivery Systems as a Potential Vaccine against Visceral Leishmaniasis: Formulation Development and Immunogenicity
  11. Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
  12. PEGylated and functionalized polylactide-based nanocapsules: An overview
  13. Vaccination with Formulation of Nanoparticles Loaded with Leishmania amazonensis Antigens Confers Protection against Experimental Visceral Leishmaniasis in Hamster
  14. Polyester Nanocapsules for Intravenous Delivery of Artemether: Formulation Development, Antimalarial Efficacy, and Cardioprotective Effects In Vivo
  15. Nanoformulations with Leishmania braziliensis Antigens Triggered Controlled Parasite Burden in Vaccinated Golden Hamster (Mesocricetus auratus) against Visceral Leishmaniasis
  16. PLA‐b‐SMA as an Amphiphilic Diblock Copolymer for Encapsulation of Lipophilic Cargo
  17. In vitro interaction of polyethylene glycol-block-poly(D,L-lactide) nanocapsule devices with host cardiomyoblasts and Trypanosoma cruzi-infective forms
  18. Photodynamic therapy with the dual-mode association of IR780 to PEG-PLA nanocapsules and the effects on human breast cancer cells
  19. Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione
  20. Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease
  21. Repositioning of Tamoxifen in Surface-Modified Nanocapsules as a Promising Oral Treatment for Visceral Leishmaniasis
  22. Release, transfer and partition of fluorescent dyes from polymeric nanocarriers to serum proteins monitored by asymmetric flow field-flow fractionation
  23. Review on Experimental Treatment Strategies Against Trypanosoma cruzi
  24. Lipid-based nanocarriers co-loaded with artemether and triglycerides of docosahexaenoic acid: Effects on human breast cancer cells
  25. Mechanistic insights into the intracellular release of doxorubicin from pH-sensitive liposomes
  26. PLA-PEG nanospheres decorated with phage display selected peptides as biomarkers for detection of human colorectal adenocarcinoma
  27. Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation
  28. Labeling PLA-PEG nanocarriers with IR780: physical entrapment versus covalent attachment to polylactide
  29. Physical and biological effects of paclitaxel encapsulation on disteraroylphosphatidylethanolamine-polyethyleneglycol polymeric micelles
  30. Lychnopholide in Poly( d , l -Lactide)- Block -Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi<...
  31. Cloxacillin nanostructured formulation for the treatment of bovine keratoconjunctivitis
  32. Benznidazole Self-Emulsifying Delivery System: A Novel Alternative Dosage Form For Chagas Disease Treatment
  33. Cloxacillin benzathine-loaded polymeric nanocapsules: Physicochemical characterization, cell uptake, and intramammary antimicrobial effect
  34. IR780-polymer conjugates for stable near-infrared labeling of biodegradable polyester-based nanocarriers
  35. Phthalocyanine photosensitizer in polyethylene glycol-block-poly(lactide-co-benzyl glycidyl ether) nanocarriers: Probing the contribution of aromatic donor-acceptor interactions in polymeric nanospheres
  36. Mechanisms of interaction of biodegradable polyester nanocapsules with non-phagocytic cells
  37. Paclitaxel-Loaded pH-Sensitive Liposome: New Insights on Structural and Physicochemical Characterization
  38. Relationship between virulence factor genes in coagulase-negative Staphylococcus spp. and failure of antimicrobial treatment of subclinical mastitis in sheep
  39. Biodistribution of free and encapsulated 99mTc-fluconazole in an infection model induced by Candida albicans
  40. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study
  41. Reduced cardiotoxicity and increased oral efficacy of artemether polymeric nanocapsules in Plasmodium berghei-infected mice
  42. Increased Body Exposure to New Anti-Trypanosomal Through Nanoencapsulation
  43. Impact of dose and surface features on plasmatic and liver concentrations of biodegradable polymeric nanocapsules
  44. Ravuconazole self-emulsifying delivery system
  45. Functional polylactide via ring-opening copolymerisation with allyl, benzyl and propargyl glycidyl ethers
  46. Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti-Trypanosomal Lychnopholide
  47. Uso de antimicrobiano nanoparticulado para o tratamento da mastite subclínica de ovelhas de corte no período seco
  48. Efficacy of Lychnopholide Polymeric Nanocapsules after Oral and Intravenous Administration in Murine Experimental Chagas Disease
  49. Polymeric nanocapsules prevent oxidation of core-loaded molecules: evidence based on the effects of docosahexaenoic acid and neuroprostane on breast cancer cells proliferation
  50. Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation
  51. Characterization and in vivo evaluation of nanocapsules loading 99mTc-MIBI for intramammary study
  52. Improvement of pharmacokinetic profile and efficacy of sesquiterpene lactone in nanocarriers in the experimental Chagas disease in mice
  53. Therapeutical approaches under investigation for treatment of Chagas disease
  54. In vivoantimalarial efficacy of acetogenins, alkaloids and flavonoids enriched fractions fromAnnona crassifloraMart.
  55. Sesquiterpene Lactone in Nanostructured Parenteral Dosage Form Is Efficacious in Experimental Chagas Disease
  56. Chloroaluminium phthalocyanine polymeric nanoparticles as photosensitisers: Photophysical and physicochemical characterisation, release and phototoxicity in vitro
  57. HPLC-DAD and UV-Spectrophotometry for the Determination of Lychnopholide in Nanocapsule Dosage Form: Validation and Application to Release Kinetic Study
  58. HPLC-FLD methods to quantify chloroaluminum phthalocyanine in nanoparticles, plasma and tissue: application in pharmacokinetic and biodistribution studies
  59. Profile of wound healing process induced by allantoin
  60. Nanotechnology applied to the treatment of malaria
  61. Biodistribution study and identification of inflammatory sites using nanocapsules labeled with 99mTc–HMPAO
  62. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of 99mTechnetium-fluconazole nanocapsules
  63. PLA-PEG nanocapsules radiolabeled with 99mTechnetium-HMPAO: Release properties and physicochemical characterization by atomic force microscopy and photon correlation spectroscopy
  64. Nanotecnologia farmacêutica aplicada ao tratamento da malária
  65. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices
  66. Surface-Modified and Conventional Nanocapsules as Novel Formulations for Parenteral Delivery of Halofantrine
  67. Poly-Caprolactone Nanocapsules Morphological Features by Atomic Force Microscopy
  68. Polymeric Nanostructures for Drug Delivery: Characterization by Atomic Force Microscopy
  69. Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice
  70. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules
  71. The antileishmanial properties of surface-modified, primaquine-loaded nanocapsules tested against intramacrophagic Leishmania donovani amastigotes in vitro
  72. A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells
  73. Poly(D,L‐Lactide) Nanocapsules Prepared by a Solvent Displacement Process: Influence of the Composition on Physicochemical and Structural Properties
  74. Interactions between a Macrophage Cell Line (J774A1) and Surface-modified Poly(D,L-lactide) Nanocapsules Bearing Poly(ethylene glycol)